This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Ethosuximide

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Ethosuximide is used mainly in the treatment of petit mal epilepsy. However, it is also useful in akinetic and myoclonic attacks associated with generalised EEG spike-and-wave paroxysms.

Occasionally it is necessary to use a combination of sodium valproate and ethosuximide to control complex absences. This combination may also be used in patients with combined absence and tonic-clonic seizures where valproate may fail to satisfactorily control the absences.

The peak serum levels of ethosuximide occur 1-4 hours after administration and the control of absence seizures is highly correlated with plasma levels.

The summary of product characteristics should be consulted before prescribing this drug.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.